< PreviousEXHIBITION GUIDE – ECCVID 202030 09:00 - 10:00 Virtual Integrated Session Channel 6 Targeting SARS-CoV-2: novel vaccines and antivirals for the prevention and treatment of COVID-19 ESCMID-appointed chair TBA 09:00 Introduction 09:05 New advances in COVID-19 vaccine development Sarah Gilbert (United Kingdom) 09:20 Exploring new therapies for COVID-19: focus on monoclonal antibodies Mark Esser (United States) 09:35 Panel Q&A Organised by Wednesday, 23 September 2020EXHIBITION GUIDE – ECCVID 202031 10:15 - 11:15 Virtual Integrated Session Channel 6 Breakthrough of pandemic times: COVID-19 faces the next pandemic ESCMID-appointed chair Eric Claas (Netherlands) Chair António M. Gonçalves (Portugal) 10:15 Early implementation of diagnostic system for COVID-19 in South Korea Hyuk Min Lee (South Korea) 10:35 Access, quality and mass testing: effective tools for public health Carlos Gouvêa (Brazil) 10:55 Need for co-testing of SARS-CoV-2 and essential respiratory viruses Anja Oštrbenk Valen č ak (Slovenia) Organised by Wednesday, 23 September 2020EXHIBITION GUIDE – ECCVID 202032 17:00 - 17:50 Virtual Integrated Session Channel 6 COVID-19 secondary infections: understanding the threat of opportunistic bacteria and fungi ESCMID-appointed chair TBA Chair Philippe Montravers (France) 17:00 Welcome and introduction 17:05 Spotlight on the management of bacterial–SARS-CoV-2 co-infections and superinfections Antoni Torres (Spain) 17:20 Invasive aspergillosis and COVID-19: uncovering the hidden threat Robert Krause (Austria) 17:35 Panel discussion Organised by Wednesday, 23 September 2020EXHIBITION GUIDE – ECCVID 202033 18:30 - 19:30 Virtual Integrated Session Channel 6 Secondary bacterial and co-infections complicating COVID-19: a comparison and contrast to influenza ESCMID-appointed chair TBA Chair Souha Kanj (Lebanon) 18:30 Welcome and opening remarks 18:35 Bacterial pneumonia complicating COVID-19 vs influenza: when and with what organisms? Ricard Ferrer (Spain) 18:47 Establishing the diagnosis of secondary bacterial pneumonia: implication on outcome Alex Soriano (Spain) 18:59 Clinical management, guidelines and treatment approaches: driven by local ecology? Susan Davis (United States) 19:11 Panel Q&A 19:26 Closing remarks Organised by Wednesday, 23 September 2020EXHIBITION GUIDE – ECCVID 202034 17:15 - 18:15 Virtual Integrated Session Channel 6 Accelerating viral research workflows, vaccine and drug development ESCMID-appointed chair TBA Chair Tracy Andrews (United Kingdom) 17:15 Recognising the immune response to SARS-CoV-2 Andrea Cossarizza (Italy) 17:45 Automated group testing at scale to enable COVID-19 decision makers Nikhil Gopalkrishnan (United States) Josie Kishi (United States) Organised by Thursday, 24 September 2020EXHIBITION GUIDE – ECCVID 202035 17:15 - 18:15 Virtual Integrated Session Channel 7 Invasive fungal infections and COVID-19: expect the unexpected? ESCMID-appointed chair Oliver Cornely (Germany) Chair Michael von Bergwelt-Baildon (Germany) 17:15 Welcome and opening remarks 17:20 Estimating the burden of COVID-19-associated fungal disease, risk factors and diagnostic challenges Paul Verweij (Netherlands) 17:35 Challenges in management of COVID-19 and fungal infection in the cancer patient: an illustrative case Dimitrios Kontoyiannis (United States) 17:50 The conundrums of COVID-19 in cancer patients: unique considerations of risk of severity and management Dimitrios Kontoyiannis (United States) 18:05 Q&A Organised by Thursday, 24 September 2020EXHIBITION GUIDE – ECCVID 202036 18:30 - 19:30 Virtual Integrated Session Channel 6 Bringing antiviral expertise to pandemic times ESCMID-appointed chair TBA Chair Andrew Ustianowski (United Kingdom) 18:30 Time to respond Andrew Ustianowski (United Kingdom) 18:45 Time to innovate Alex Soriano (Spain) 19:00 Time to collaborate Raffaele Bruno (Italy) 19:15 Time to discuss Organised by Friday, 25 September 2020EXHIBITION GUIDE – ECCVID 202038 Abbott 100 Abbott Park Road 60064 Chicago United States www.globalpointofcare.abbott Abbott is the global leader in point- of-care (POC) diagnostics with the broadest portfolio of best-in-class rapid tests, services, and handheld devices across all healthcare settings: the lab, the clinic, remote healthcare out- posts, retail outlets, the patient’s bedside and at home. Abbott’s offering of indus- try-leading near patient tests and services is unmatched across key health and therapeutic areas, including: infectious disease, cardiometabolic & informatics, toxicology and consumer diagnostics. Exhibitor/Sponsor Profiles DIAGNOSTICS EPIDEMIOLOGY - LOCAL, REGIONAL, GLOBAL AND DIAGNOSTICSEXHIBITION GUIDE – ECCVID 202039 AB ANALITICA Srl Via Svizzera 16 35127 Padova Italy www.abanalitica.com AB ANALITICA is specialized in re- search, development and production of advanced molecular diagnostic solutions based on real time PCR, Re- verse line blot and NGS technologies. From the beginning of COVID-19 pan- demic, AB ANALITICA has been con- stantly committed in the development and production of SARS-CoV-2 screening solutions “sample to result”. Our solution includes two One Step real-timePCR kits for SARS-CoV-2 detection together with our branded Genequality X120 automated platform. By the enhancement of our production facilities AB ANALITICA has been able to provide our customers all over Italy, with a very high quantity of machines and product in a relatively short time. Exhibitor/Sponsor Profiles DIAGNOSTICS EPIDEMIOLOGY - LOCAL, REGIONAL, GLOBAL AND DIAGNOSTICS INFECTION CONTROL PREPAREDNESS AND RESPONSENext >